Joshua Brumm
Président chez Amphista Therapeutics Ltd.
Fortune : 767 830 $ au 31/05/2024
Profil
Joshua T.
Brumm was the founder and had founded Water Street Solutions, Inc. in 2002, where he served as the Chief Executive Officer from 2002 to 2007.
He currently holds the position of Chairman at Amphista Therapeutics Ltd.
and is an Advisor at Atlas Venture Advisors, Inc. Mr. Brumm's former positions include being the President, CEO, Secretary & Director at Dyne Therapeutics, Inc. from 2019 to 2024, Finance Director at Proteolix, Inc. in 2009, Executive VP, Chief Financial & Accounting Officer at Pharmacyclics LLC from 2012 to 2013, CFO, Senior VP & Head-Investor Relations at ZELTIQ Aesthetics, Inc. in 2009, Chief Operating & Financial Officer at Versartis, Inc. in 2013, Chief Operating & Financial Officer at Kaleido Biosciences, Inc. from 2018 to 2019, and COO & CFO at Aravive, Inc. from 2013 to 2017.
Mr. Brumm obtained his undergraduate degree from the University of Notre Dame in 2004.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DYNE THERAPEUTICS INC
0,02% | 31/03/2024 | 24 085 ( 0,02% ) | 767 830 $ | 31/05/2024 |
Postes actifs de Joshua Brumm
| Sociétés | Poste | Début |
|---|---|---|
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Président | 21/09/2021 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
Anciens postes connus de Joshua Brumm
| Sociétés | Poste | Fin |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Directeur Général | 25/03/2024 |
| KALEIDO BIOSCIENCES, INC. | Directeur Financier/CFO | 11/10/2019 |
| ARAVIVE, INC. | Directeur Financier/CFO | 31/12/2017 |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Directeur Financier/CFO | 01/12/2017 |
| PHARMACYCLICS, INC. | Directeur Financier/CFO | 14/08/2013 |
Formation de Joshua Brumm
| University of Notre Dame | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| ARAVIVE, INC. | Health Technology |
| DYNE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
ZELTIQ Aesthetics, Inc.
 ZELTIQ Aesthetics, Inc. Medical SpecialtiesHealth Technology ZELTIQ Aesthetics, Inc. is a medical technology company, which focuses on developing and commercializing products. Its product, the coolsculpting system is designed to selectively reduce stubborn fat bulges. The company was founded by Mitchell E. Levinson in 2005 and is headquartered in North Chicago, IL. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Water Street Solutions, Inc.
 Water Street Solutions, Inc. Water UtilitiesUtilities Part of Advanced Water Recovery, Water Street Solutions, Inc. provides industrial water and wastewater treatment systems and services. The company is based in Peoria, IL. Water Street Solutions was acquired by Advanced Water Recovery on February 01, 2014. | Utilities |
Amphista Therapeutics Ltd.
Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Health Technology |
